MRVI:NASDAQMaravai LifeSciences Holdings, Inc. Analysis

Maravai LifeSciences (MRVI) is currently trading at $4.08, comfortably above its 20‑day SMA of $3.96 and the 50‑day SMA of $3.47, indicating a short‑term bullish bias. The RSI sits at 55, suggesting the stock is neither overbought nor oversold, while the MACD histogram is slightly negative, hinting at a modest near‑term downside pressure. Volume has been increasing, supporting the upward price momentum, yet the 30‑day volatility of over 80% and a computed beta of 2.1 signal a highly volatile and market‑sensitive profile. On the fundamentals side, MRVI posted a 40.5% revenue surge to $204.7 M, but profitability remains weak with a –51% net margin and negative cash flows. The balance sheet shows $165.9 M in cash offset by $315 M of debt, yielding a debt‑to‑equity ratio above 85%, which raises concerns about financial flexibility. Analysts have upgraded the stock to a “Buy” with a median price target of $6.00, implying roughly 40% upside from current levels.